Continue on to learn about the remaining stocks, Microba Life Sciences (ASX:MAP) and Monash IVF (ASX:MVF), as well as what to expect from these companies in 2023.

In this video, Dr. Tara discusses:
- (0:34) Impacts of Ferring's FDA approval on Microba
- (5:30) Drivers behind Microba's increase in revenue
- (7:12) What 2023 looks like for Monash IVF
- (8:39) Monash IVF's rating
- (11:45) Monash IVF's impact from legal action

Note: This interview was filmed on 7 February 2023.